Bionova Scientific, a biologics CDMO, introduced a COVID-19 support program, making lab capacity available to industry partners impacted by COVID-19 shutdowns. Organizations developing COVID-19 related treatments will be given priority access through the program. “We recognize that the capacity of the industry we serve has been severely impacted by this crisis. Meanwhile, the development timelines for new therapeutics remain as urgent as ever,” said Bionova CEO Amy Kong. “This has coincided w...